DUBLIN – Shares in Erytech SA took a hammering Monday on news that the company is halting development of its lead program, eryaspase, in acute lymphoblastic leukemia (ALL) and withdrawing a marketing authorization application (MAA) in Europe for relapsed and refractory (r/r) ALL.